| Mar-2025 | Dec-2024 | Dec-2024 | Sep-2024 | Jul-2024 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 6.31% | 6.31% | 6.31% | 6.31% | 7.75% |
Indian | 39.45% | 39.44% | 39.44% | 39.44% | 58.9% |
Total Promoter | - | - | - | - | - |
Institutions | 13.82% | 24.12% | 16.03% | 24.12% | 33.33% |
Non-Institutions | 40.4% | 30.11% | 38.2% | 30.11% | 0% |
Total Non-Promoter | 54.22% | 54.23% | 54.23% | 54.23% | 33.33% |
Custodian | 0% | 0% | 0% | 0% | 0% |
Total | 100% | 100% | 100% | 100% | 100% |
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Senores Pharmaceuticals shares closed 6% below their listing price, although they are still up 43% from the IPO price.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
